Cardiac and multiorgan transplantation for end-stage congenital heart disease

Jeffrey A. Robinson, David J. Driscoll, Patrick W. O'Leary, Harold M. Burkhart, Joseph A. Dearani, Richard C. Daly, Brooks Sayre Edwards, Sonja H. Dahl, Jonathan N. Johnson

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Objective: To report our single-center experience with patients who had cardiac and multiorgan transplantation for end-stage congenital heart disease (CHD). Patients and Methods: We reviewed records for all patients with CHD who had undergone heart transplantation at Mayo Clinic, Rochester, Minnesota, from November 1, 1990, through June 30, 2012. Patients with cardiomyopathy were excluded, unless CHD was present. Results: Overall, 45 patients had cardiac transplantation for end-stage CHD (mean age, 26.1±18.4 years; range, 1 month to 65 years). Two patients (4%) had combined heart/liver transplantation; 1 (2%) had heart/kidney transplantation. Six patients (13%) had no previous cardiac operation; the remaining 39 patients had a mean of 3 (range, 1-8) previous cardiac operations. Patient survival (95% CI) at 1, 5, and 10 years was 89% (80%-98%), 89% (80%-98%), and 72% (56%-87%), respectively, while graft survival at 1, 5, and 10 years was 89% (80%-98%), 89% (80%-98%), and 61% (44%-78%), respectively. During the same era, the International Society for Heart & Lung Transplantation reported that survival in patients undergoing transplant for non-congenital diagnoses was 85%, 72%, and 56%, respectively. Over a mean follow-up of 8.7±6.2 years, rejection requiring treatment was documented in 35 patients (78%). Eleven patients (24%) have been diagnosed with neoplasia (8 skin, 1 blood, 1 lymph, and 1 other), and 3 patients (7%) have required retransplantation. Four patients (9%) have developed significant coronary vasculopathy; 1 successfully underwent retransplantation, and 3 died 6, 8, and 14 years after transplantation. Conclusion: With appropriate patient selection and posttransplant monitoring, survival has improved for patients with complex end-stage CHD. Multiorgan transplantation is an option for selected patients with CHD.

Original languageEnglish (US)
Pages (from-to)478-483
Number of pages6
JournalMayo Clinic Proceedings
Volume89
Issue number4
DOIs
StatePublished - 2014

Fingerprint

Heart Transplantation
Heart Diseases
Survival
Transplantation
Lung Transplantation
Lymph
Graft Survival
Cardiomyopathies
Liver Transplantation
Kidney Transplantation
Patient Selection

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Robinson, J. A., Driscoll, D. J., O'Leary, P. W., Burkhart, H. M., Dearani, J. A., Daly, R. C., ... Johnson, J. N. (2014). Cardiac and multiorgan transplantation for end-stage congenital heart disease. Mayo Clinic Proceedings, 89(4), 478-483. https://doi.org/10.1016/j.mayocp.2013.11.019

Cardiac and multiorgan transplantation for end-stage congenital heart disease. / Robinson, Jeffrey A.; Driscoll, David J.; O'Leary, Patrick W.; Burkhart, Harold M.; Dearani, Joseph A.; Daly, Richard C.; Edwards, Brooks Sayre; Dahl, Sonja H.; Johnson, Jonathan N.

In: Mayo Clinic Proceedings, Vol. 89, No. 4, 2014, p. 478-483.

Research output: Contribution to journalArticle

Robinson, JA, Driscoll, DJ, O'Leary, PW, Burkhart, HM, Dearani, JA, Daly, RC, Edwards, BS, Dahl, SH & Johnson, JN 2014, 'Cardiac and multiorgan transplantation for end-stage congenital heart disease', Mayo Clinic Proceedings, vol. 89, no. 4, pp. 478-483. https://doi.org/10.1016/j.mayocp.2013.11.019
Robinson JA, Driscoll DJ, O'Leary PW, Burkhart HM, Dearani JA, Daly RC et al. Cardiac and multiorgan transplantation for end-stage congenital heart disease. Mayo Clinic Proceedings. 2014;89(4):478-483. https://doi.org/10.1016/j.mayocp.2013.11.019
Robinson, Jeffrey A. ; Driscoll, David J. ; O'Leary, Patrick W. ; Burkhart, Harold M. ; Dearani, Joseph A. ; Daly, Richard C. ; Edwards, Brooks Sayre ; Dahl, Sonja H. ; Johnson, Jonathan N. / Cardiac and multiorgan transplantation for end-stage congenital heart disease. In: Mayo Clinic Proceedings. 2014 ; Vol. 89, No. 4. pp. 478-483.
@article{f75de1c0b99a4a2e860c6903733177f4,
title = "Cardiac and multiorgan transplantation for end-stage congenital heart disease",
abstract = "Objective: To report our single-center experience with patients who had cardiac and multiorgan transplantation for end-stage congenital heart disease (CHD). Patients and Methods: We reviewed records for all patients with CHD who had undergone heart transplantation at Mayo Clinic, Rochester, Minnesota, from November 1, 1990, through June 30, 2012. Patients with cardiomyopathy were excluded, unless CHD was present. Results: Overall, 45 patients had cardiac transplantation for end-stage CHD (mean age, 26.1±18.4 years; range, 1 month to 65 years). Two patients (4{\%}) had combined heart/liver transplantation; 1 (2{\%}) had heart/kidney transplantation. Six patients (13{\%}) had no previous cardiac operation; the remaining 39 patients had a mean of 3 (range, 1-8) previous cardiac operations. Patient survival (95{\%} CI) at 1, 5, and 10 years was 89{\%} (80{\%}-98{\%}), 89{\%} (80{\%}-98{\%}), and 72{\%} (56{\%}-87{\%}), respectively, while graft survival at 1, 5, and 10 years was 89{\%} (80{\%}-98{\%}), 89{\%} (80{\%}-98{\%}), and 61{\%} (44{\%}-78{\%}), respectively. During the same era, the International Society for Heart & Lung Transplantation reported that survival in patients undergoing transplant for non-congenital diagnoses was 85{\%}, 72{\%}, and 56{\%}, respectively. Over a mean follow-up of 8.7±6.2 years, rejection requiring treatment was documented in 35 patients (78{\%}). Eleven patients (24{\%}) have been diagnosed with neoplasia (8 skin, 1 blood, 1 lymph, and 1 other), and 3 patients (7{\%}) have required retransplantation. Four patients (9{\%}) have developed significant coronary vasculopathy; 1 successfully underwent retransplantation, and 3 died 6, 8, and 14 years after transplantation. Conclusion: With appropriate patient selection and posttransplant monitoring, survival has improved for patients with complex end-stage CHD. Multiorgan transplantation is an option for selected patients with CHD.",
author = "Robinson, {Jeffrey A.} and Driscoll, {David J.} and O'Leary, {Patrick W.} and Burkhart, {Harold M.} and Dearani, {Joseph A.} and Daly, {Richard C.} and Edwards, {Brooks Sayre} and Dahl, {Sonja H.} and Johnson, {Jonathan N.}",
year = "2014",
doi = "10.1016/j.mayocp.2013.11.019",
language = "English (US)",
volume = "89",
pages = "478--483",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "4",

}

TY - JOUR

T1 - Cardiac and multiorgan transplantation for end-stage congenital heart disease

AU - Robinson, Jeffrey A.

AU - Driscoll, David J.

AU - O'Leary, Patrick W.

AU - Burkhart, Harold M.

AU - Dearani, Joseph A.

AU - Daly, Richard C.

AU - Edwards, Brooks Sayre

AU - Dahl, Sonja H.

AU - Johnson, Jonathan N.

PY - 2014

Y1 - 2014

N2 - Objective: To report our single-center experience with patients who had cardiac and multiorgan transplantation for end-stage congenital heart disease (CHD). Patients and Methods: We reviewed records for all patients with CHD who had undergone heart transplantation at Mayo Clinic, Rochester, Minnesota, from November 1, 1990, through June 30, 2012. Patients with cardiomyopathy were excluded, unless CHD was present. Results: Overall, 45 patients had cardiac transplantation for end-stage CHD (mean age, 26.1±18.4 years; range, 1 month to 65 years). Two patients (4%) had combined heart/liver transplantation; 1 (2%) had heart/kidney transplantation. Six patients (13%) had no previous cardiac operation; the remaining 39 patients had a mean of 3 (range, 1-8) previous cardiac operations. Patient survival (95% CI) at 1, 5, and 10 years was 89% (80%-98%), 89% (80%-98%), and 72% (56%-87%), respectively, while graft survival at 1, 5, and 10 years was 89% (80%-98%), 89% (80%-98%), and 61% (44%-78%), respectively. During the same era, the International Society for Heart & Lung Transplantation reported that survival in patients undergoing transplant for non-congenital diagnoses was 85%, 72%, and 56%, respectively. Over a mean follow-up of 8.7±6.2 years, rejection requiring treatment was documented in 35 patients (78%). Eleven patients (24%) have been diagnosed with neoplasia (8 skin, 1 blood, 1 lymph, and 1 other), and 3 patients (7%) have required retransplantation. Four patients (9%) have developed significant coronary vasculopathy; 1 successfully underwent retransplantation, and 3 died 6, 8, and 14 years after transplantation. Conclusion: With appropriate patient selection and posttransplant monitoring, survival has improved for patients with complex end-stage CHD. Multiorgan transplantation is an option for selected patients with CHD.

AB - Objective: To report our single-center experience with patients who had cardiac and multiorgan transplantation for end-stage congenital heart disease (CHD). Patients and Methods: We reviewed records for all patients with CHD who had undergone heart transplantation at Mayo Clinic, Rochester, Minnesota, from November 1, 1990, through June 30, 2012. Patients with cardiomyopathy were excluded, unless CHD was present. Results: Overall, 45 patients had cardiac transplantation for end-stage CHD (mean age, 26.1±18.4 years; range, 1 month to 65 years). Two patients (4%) had combined heart/liver transplantation; 1 (2%) had heart/kidney transplantation. Six patients (13%) had no previous cardiac operation; the remaining 39 patients had a mean of 3 (range, 1-8) previous cardiac operations. Patient survival (95% CI) at 1, 5, and 10 years was 89% (80%-98%), 89% (80%-98%), and 72% (56%-87%), respectively, while graft survival at 1, 5, and 10 years was 89% (80%-98%), 89% (80%-98%), and 61% (44%-78%), respectively. During the same era, the International Society for Heart & Lung Transplantation reported that survival in patients undergoing transplant for non-congenital diagnoses was 85%, 72%, and 56%, respectively. Over a mean follow-up of 8.7±6.2 years, rejection requiring treatment was documented in 35 patients (78%). Eleven patients (24%) have been diagnosed with neoplasia (8 skin, 1 blood, 1 lymph, and 1 other), and 3 patients (7%) have required retransplantation. Four patients (9%) have developed significant coronary vasculopathy; 1 successfully underwent retransplantation, and 3 died 6, 8, and 14 years after transplantation. Conclusion: With appropriate patient selection and posttransplant monitoring, survival has improved for patients with complex end-stage CHD. Multiorgan transplantation is an option for selected patients with CHD.

UR - http://www.scopus.com/inward/record.url?scp=84898664201&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898664201&partnerID=8YFLogxK

U2 - 10.1016/j.mayocp.2013.11.019

DO - 10.1016/j.mayocp.2013.11.019

M3 - Article

C2 - 24684872

AN - SCOPUS:84898664201

VL - 89

SP - 478

EP - 483

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 4

ER -